Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at sammenligne standardterapi til behandling af Hodgkin-lymfom med brugen af ​​to lægemidler, Brentuximab Vedotin og Nivolumab

4. november 2026 opdateret af: National Cancer Institute (NCI)

Et randomiseret fase 3 interim respons tilpasset forsøg, der sammenligner standardterapi med immunonkologisk terapi til børn og voksne med nyligt diagnosticeret stadium I og II klassisk Hodgkin-lymfom

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.

SECONDARY OBJECTIVES:

I. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a RER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To evaluate the overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a SER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

III. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients.

IV. To evaluate in patients with newly diagnosed early stage cHL the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in the overall cohort, in the favorable risk cohort, and in the unfavorable risk cohort.

V. To evaluate the event-free survival (EFS) at 12 years of patients undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab).

VI. To compare the physician-reported treatment-related adverse event (AE) rates between a standard chemotherapy approach and an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL.

VII. To compare patient-reported adverse events using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), stratified by age groups, therapeutic arms, and receipt of radiation therapy (RT) over time.

VIII. To evaluate changes in patient-reported fatigue, cognitive functioning, and health-related quality of life (HRQoL), e.g., emotional, physical, and role functioning, by treatment arm, using validated adult and pediatric measurement systems.

IX. To evaluate self-reported late morbidities (e.g., cardiovascular, pulmonary and endocrine) over time for children, adolescents and adults undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab) with and without RT using measures from the St. Jude Lifetime Cohort Study (SJLIFE).

X. To evaluate fludeoxyglucose F-18 (FDG)-position emission tomography (PET) measurements of metabolic tumor burden (MTV and total lesion glycolysis [TLG]) at PET at baseline (PET1) as a predictive marker of PFS.

XI. To evaluate the associations between race/ethnicity and key outcomes including early response to therapy, PFS and OS.

EXPLORATORY OBJECTIVES:

I. To evaluate the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL across different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years).

II. To bank specimens for future correlative studies. III. To assess concordance and discordance of rapid central review and local institutional review of FDG PET 5-point score (5-PS; previously referred to as Deauville score) at baseline PET1, interim PET2 and end of systemic therapy PET-end of systemic therapy (EST) SER.

IV. To assess the association between PFS and the quantitative FDG-PET/computed tomography (CT) parameters (PET MTV, TLG, delta-standardized uptake value [SUV] and PET SUV-based quantitative surrogates [qPET] of visual qualitative 5-PS) on measurements by automated measurements using convolutional neural networks (CNNs) through artificial-intelligence (AI) machine learning in the entire population.

V. To assess the agreement between quantitative FDG-PET/CT parameters obtained using AI and those based on measurements by a trained imaging physician.

VI. To compare patient-reported adverse events (via pediatric [Ped]-PRO-CTCAE and PRO-CTCAE) to provider adverse event reporting.

VII. To evaluate the association between self-reported race/ethnicity and social determinants of health.

VIII. To evaluate the associations between race/ethnicity and post-progression/post-relapse overall survival.

IX. To evaluate the completion rates of PRO and health-related quality of life (HRQoL) contact forms at 1 year off treatment for the first 450 eligible patients.

X. To collect contact information from participants for future re-contact.

OUTLINE: Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride intravenously [IV] over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or magnetic resonance imaging (MRI) and are identified as RER or SER.

Patients with a favorable risk status and RER are randomized to Arm A or Arm B. Patients with a favorable risk status and SER are randomized to Arm C or Arm D. Patients with an unfavorable risk status and RER are randomized to Arm E or Arm F. Patients with an unfavorable risk status and SER are randomized to Arm G or Arm H.

ARM A (RER, FAVORABLE): Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM B (RER, FAVORABLE): Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM C (SER, FAVORABLE): Patients receive either the eBEACOPP regimen (doxorubicin hydrochloride IV over 3-15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone orally [PO] twice daily [BID] on days 1-14, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV over at least 10 minutes on day 8, and vincristine sulfate IV on day 8 of each cycle) or the eBPDac regimen (doxorubicin hydrochloride IV 3-15 minutes on day 1, cyclophosphamide IV 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone PO BID on days 1-14, dacarbazine IV over 15-60 minutes on days 2 & 3, bleomycin sulfate IV over at least 10 minutes on day 4, 5, 6, 7, or 8, vincristine sulfate IV on day 4, 5, 6, 7, or 8 of each cycle). Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM D (SER, FAVORABLE): Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM E (RER, UNFAVORABLE): Patients receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM F (RER, UNFAVORABLE): Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM G (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.

ARM H (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.

After completion of study treatment, patients are followed up every 3 months for the first year, then every 6 months for the second and third year, then annually until 12 years from date of registration.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1875

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Québec, Canada, G1V 4G2
        • Rekruttering
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • Ledende efterforsker:
          • Bruno Michon
        • Kontakt:
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Rekruttering
        • Alberta Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Victor A. Lewis
      • Edmonton, Alberta, Canada, T6G 2B7
        • Rekruttering
        • University of Alberta Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Sarah J. McKillop
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • Rekruttering
        • British Columbia Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 6477 604-875-2345
        • Ledende efterforsker:
          • Rebecca J. Deyell
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Rekruttering
        • CancerCare Manitoba
        • Kontakt:
        • Ledende efterforsker:
          • Stephanie M. Villeneuve
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Rekruttering
        • IWK Health Centre
        • Kontakt:
        • Ledende efterforsker:
          • Chelsea Ash
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Rekruttering
        • McMaster Children's Hospital at Hamilton Health Sciences
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 905-521-2100
        • Ledende efterforsker:
          • Uma H. Athale
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 519-685-8306
        • Ledende efterforsker:
          • Shayna M. Zelcer
      • Ottawa, Ontario, Canada, K1H 8L1
        • Rekruttering
        • Children's Hospital of Eastern Ontario
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 613-737-7600
        • Ledende efterforsker:
          • Donna L. Johnston
      • Toronto, Ontario, Canada, M5G 1X8
        • Rekruttering
        • Hospital for Sick Children
        • Kontakt:
        • Ledende efterforsker:
          • Angela S. Punnett
    • Quebec
      • Montreal, Quebec, Canada, H3H 1P3
        • Rekruttering
        • The Montreal Children's Hospital of the MUHC
        • Kontakt:
        • Ledende efterforsker:
          • Stephanie Mourad
      • Montreal, Quebec, Canada, H3T 1C5
        • Rekruttering
        • Centre Hospitalier Universitaire Sainte-Justine
        • Ledende efterforsker:
          • Monia Marzouki
        • Kontakt:
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Rekruttering
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • Kontakt:
        • Ledende efterforsker:
          • Stephanie Vairy
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Rekruttering
        • Jim Pattison Children's Hospital
        • Ledende efterforsker:
          • Kathleen Felton
        • Kontakt:
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Rekruttering
        • Children's Hospital of Alabama
        • Ledende efterforsker:
          • Ana C. Xavier
        • Kontakt:
      • Mobile, Alabama, Forenede Stater, 36604
        • Rekruttering
        • USA Health Strada Patient Care Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-388-8721
        • Ledende efterforsker:
          • Hamayun Imran
    • Alaska
      • Anchorage, Alaska, Forenede Stater, 99508
    • Arizona
      • Goodyear, Arizona, Forenede Stater, 85338
        • Rekruttering
        • CTCA at Western Regional Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 623-207-3000
        • Ledende efterforsker:
          • Sarah Monick
      • Mesa, Arizona, Forenede Stater, 85202
        • Rekruttering
        • Banner Children's at Desert
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 480-412-3100
        • Ledende efterforsker:
          • Joseph C. Torkildson
      • Phoenix, Arizona, Forenede Stater, 85016
        • Rekruttering
        • Phoenix Childrens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 602-546-0920
        • Ledende efterforsker:
          • Alexandra M. Walsh
      • Phoenix, Arizona, Forenede Stater, 85004
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72202-3591
        • Rekruttering
        • Arkansas Children's Hospital
        • Ledende efterforsker:
          • Michael W. Bishop
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 501-364-7373
    • California
      • Carmichael, California, Forenede Stater, 95608
      • Carmichael, California, Forenede Stater, 95608
      • Corona, California, Forenede Stater, 92882
        • Rekruttering
        • City of Hope Corona
        • Ledende efterforsker:
          • Alex F. Herrera
        • Kontakt:
      • Costa Mesa, California, Forenede Stater, 92627
        • Rekruttering
        • UC Irvine Health Cancer Center-Newport
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-827-8839
        • Ledende efterforsker:
          • Nicole Foley
      • Downey, California, Forenede Stater, 90242
        • Rekruttering
        • Kaiser Permanente Downey Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 626-564-3455
        • Ledende efterforsker:
          • Robert M. Cooper
      • Duarte, California, Forenede Stater, 91010
        • Rekruttering
        • City of Hope Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Alex F. Herrera
      • Dublin, California, Forenede Stater, 94568
        • Rekruttering
        • Kaiser Permanente Dublin
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Elk Grove, California, Forenede Stater, 95758
      • Fremont, California, Forenede Stater, 94538
        • Rekruttering
        • Kaiser Permanente-Fremont
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Fresno, California, Forenede Stater, 93720
        • Rekruttering
        • Kaiser Permanente-Fresno
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Fresno, California, Forenede Stater, 93720
        • Suspenderet
        • Kaiser Permanente Fresno Orchard Plaza
      • Huntington Beach, California, Forenede Stater, 92648
        • Rekruttering
        • City of Hope Seacliff
        • Ledende efterforsker:
          • Alex F. Herrera
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 626-256-4673
      • Irvine, California, Forenede Stater, 92618
        • Rekruttering
        • City of Hope at Irvine Lennar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-467-3411
        • Ledende efterforsker:
          • Alex F. Herrera
      • Irvine, California, Forenede Stater, 92612
        • Rekruttering
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Kontakt:
        • Ledende efterforsker:
          • Nicole Foley
      • Lancaster, California, Forenede Stater, 93534
        • Rekruttering
        • City of Hope Antelope Valley
        • Kontakt:
        • Ledende efterforsker:
          • Alex F. Herrera
      • Loma Linda, California, Forenede Stater, 92354
        • Rekruttering
        • Loma Linda University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 909-558-4050
        • Ledende efterforsker:
          • Albert Kheradpour
      • Long Beach, California, Forenede Stater, 90806
        • Rekruttering
        • Miller Children's and Women's Hospital Long Beach
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 562-933-5600
        • Ledende efterforsker:
          • Jacqueline N. Casillas
      • Long Beach, California, Forenede Stater, 90813
        • Rekruttering
        • City of Hope at Long Beach Elm
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-467-3411
        • Ledende efterforsker:
          • Alex F. Herrera
      • Los Angeles, California, Forenede Stater, 90027
        • Rekruttering
        • Children's Hospital Los Angeles
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 323-361-4110
        • Ledende efterforsker:
          • Andrew Doan
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Ledende efterforsker:
          • Nicole M. Baca
        • Kontakt:
      • Madera, California, Forenede Stater, 93636
        • Rekruttering
        • Valley Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Ruetima Titapiwatanakun
      • Modesto, California, Forenede Stater, 95356
        • Rekruttering
        • Kaiser Permanente-Modesto
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Modesto, California, Forenede Stater, 95356
        • Suspenderet
        • Kaiser Permanente- Modesto MOB II
      • Newport Beach, California, Forenede Stater, 92660
        • Rekruttering
        • City of Hope Newport Beach
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-467-3411
        • Ledende efterforsker:
          • Alex F. Herrera
      • Oakland, California, Forenede Stater, 94611
        • Rekruttering
        • Kaiser Permanente-Oakland
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Aarati V. Rao
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • Children's Hospital of Orange County
        • Kontakt:
        • Ledende efterforsker:
          • Elyssa M. Rubin
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Nicole Foley
      • Rocklin, California, Forenede Stater, 95765
      • Sacramento, California, Forenede Stater, 95814
        • Rekruttering
        • Kaiser Permanente Downtown Commons
        • Ledende efterforsker:
          • Sachdev P. Thomas
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: kpoct@kp.org
      • Sacramento, California, Forenede Stater, 95816
      • Sacramento, California, Forenede Stater, 95823
        • Rekruttering
        • Kaiser Permanente-South Sacramento
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Sacramento, California, Forenede Stater, 95816
      • San Diego, California, Forenede Stater, 92123
        • Rekruttering
        • Rady Children's Hospital - San Diego
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 858-966-5934
        • Ledende efterforsker:
          • William D. Roberts
      • San Diego, California, Forenede Stater, 92134
        • Rekruttering
        • Naval Medical Center -San Diego
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 619-532-8712
        • Ledende efterforsker:
          • Yoko T. Udaka
      • San Francisco, California, Forenede Stater, 94115
        • Rekruttering
        • Kaiser Permanente-San Francisco
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • San Jose, California, Forenede Stater, 95119
        • Rekruttering
        • Kaiser Permanente-Santa Teresa-San Jose
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • San Leandro, California, Forenede Stater, 94577
        • Rekruttering
        • Kaiser Permanente San Leandro
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • San Rafael, California, Forenede Stater, 94903
        • Rekruttering
        • Kaiser San Rafael-Gallinas
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Santa Barbara, California, Forenede Stater, 93102
        • Rekruttering
        • Santa Barbara Cottage Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 805-682-7300
        • Ledende efterforsker:
          • Shivani Upadhyay
      • Santa Rosa, California, Forenede Stater, 95403
        • Rekruttering
        • Kaiser Permanente-Santa Rosa
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • South Pasadena, California, Forenede Stater, 91030
        • Rekruttering
        • City of Hope South Pasadena
        • Kontakt:
        • Ledende efterforsker:
          • Alex F. Herrera
      • South San Francisco, California, Forenede Stater, 94080
        • Rekruttering
        • Kaiser Permanente-South San Francisco
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Torrance, California, Forenede Stater, 90503
        • Rekruttering
        • City of Hope South Bay
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-467-3411
        • Ledende efterforsker:
          • Alex F. Herrera
      • Upland, California, Forenede Stater, 91786
        • Rekruttering
        • City of Hope Upland
        • Kontakt:
        • Ledende efterforsker:
          • Alex F. Herrera
      • Vallejo, California, Forenede Stater, 94589
        • Rekruttering
        • Kaiser Permanente-Vallejo
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Walnut Creek, California, Forenede Stater, 94596
        • Rekruttering
        • Kaiser Permanente-Walnut Creek
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Ledende efterforsker:
          • Sachdev P. Thomas
      • Woodland, California, Forenede Stater, 95695
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • Children's Hospital Colorado
        • Kontakt:
        • Ledende efterforsker:
          • Kelly W. Maloney
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • UCHealth University of Colorado Hospital
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 720-848-0650
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Rekruttering
        • UCHealth Memorial Hospital Central
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 719-365-2406
      • Colorado Springs, Colorado, Forenede Stater, 80920
        • Rekruttering
        • Memorial Hospital North
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 719-364-6700
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Florence Choo
      • Fort Collins, Colorado, Forenede Stater, 80524
        • Rekruttering
        • Poudre Valley Hospital
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 970-297-6150
      • Fort Collins, Colorado, Forenede Stater, 80528
        • Rekruttering
        • Cancer Care and Hematology-Fort Collins
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
      • Greeley, Colorado, Forenede Stater, 80631
        • Rekruttering
        • UCHealth Greeley Hospital
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
      • Loveland, Colorado, Forenede Stater, 80538
        • Rekruttering
        • Medical Center of the Rockies
        • Ledende efterforsker:
          • Sarah Milgrom
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 970-203-7083
    • Connecticut
      • Derby, Connecticut, Forenede Stater, 06418
        • Rekruttering
        • Smilow Cancer Hospital-Derby Care Center
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Fairfield, Connecticut, Forenede Stater, 06824
        • Rekruttering
        • Smilow Cancer Hospital Care Center-Fairfield
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Glastonbury, Connecticut, Forenede Stater, 06033
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Glastonbury
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Greenwich, Connecticut, Forenede Stater, 06830
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Greenwich
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Guilford, Connecticut, Forenede Stater, 06437
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Guilford
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Hartford, Connecticut, Forenede Stater, 06106
        • Rekruttering
        • Connecticut Children's Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 860-545-9981
        • Ledende efterforsker:
          • Michael S. Isakoff
      • Hartford, Connecticut, Forenede Stater, 06105
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Saint Francis
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • New Haven, Connecticut, Forenede Stater, 06520
        • Rekruttering
        • Yale University
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • North Haven, Connecticut, Forenede Stater, 06473
        • Rekruttering
        • Yale-New Haven Hospital North Haven Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Stamford, Connecticut, Forenede Stater, 06902
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Torrington, Connecticut, Forenede Stater, 06790
        • Rekruttering
        • Smilow Cancer Hospital-Torrington Care Center
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Trumbull, Connecticut, Forenede Stater, 06611
        • Rekruttering
        • Smilow Cancer Hospital Care Center-Trumbull
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Waterbury, Connecticut, Forenede Stater, 06708
        • Rekruttering
        • Smilow Cancer Hospital-Waterbury Care Center
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
      • Waterford, Connecticut, Forenede Stater, 06385
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Waterford
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
    • Delaware
      • Wilmington, Delaware, Forenede Stater, 19803
        • Rekruttering
        • Alfred I duPont Hospital for Children
        • Kontakt:
        • Ledende efterforsker:
          • Vibhuti Agarwal
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Rekruttering
        • Children's National Medical Center
        • Ledende efterforsker:
          • Jeffrey S. Dome
        • Kontakt:
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • Rekruttering
        • MedStar Georgetown University Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 202-444-2223
        • Ledende efterforsker:
          • Caileigh Pudela
    • Florida
      • Fort Lauderdale, Florida, Forenede Stater, 33316
        • Rekruttering
        • Broward Health Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Hector M. Rodriguez-Cortes
      • Fort Myers, Florida, Forenede Stater, 33908
        • Rekruttering
        • Golisano Children's Hospital of Southwest Florida
        • Kontakt:
        • Ledende efterforsker:
          • Emad K. Salman
      • Gainesville, Florida, Forenede Stater, 32610
        • Rekruttering
        • UF Health Cancer Institute - Gainesville
        • Ledende efterforsker:
          • Brian Stover
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 352-273-8010
      • Hollywood, Florida, Forenede Stater, 33021
        • Rekruttering
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 954-265-1847
          • E-mail: OHR@mhs.net
        • Ledende efterforsker:
          • Iftikhar Hanif
      • Jacksonville, Florida, Forenede Stater, 32207
        • Rekruttering
        • Nemours Children's Clinic-Jacksonville
        • Kontakt:
        • Ledende efterforsker:
          • Vibhuti Agarwal
      • Jacksonville, Florida, Forenede Stater, 32224-9980
        • Rekruttering
        • Mayo Clinic in Florida
        • Ledende efterforsker:
          • Mira Kohorst
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
      • Miami, Florida, Forenede Stater, 33155
        • Rekruttering
        • Nicklaus Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-624-2778
        • Ledende efterforsker:
          • Ziad A. Khatib
      • Miami, Florida, Forenede Stater, 33136
        • Suspenderet
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami Beach, Florida, Forenede Stater, 33140
        • Rekruttering
        • Mount Sinai Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jacqueline C. Barrientos
      • Orlando, Florida, Forenede Stater, 32806
        • Rekruttering
        • Arnold Palmer Hospital for Children
        • Kontakt:
        • Ledende efterforsker:
          • Zhongbo Hu
      • Orlando, Florida, Forenede Stater, 32827
        • Rekruttering
        • Nemours Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Vibhuti Agarwal
      • Orlando, Florida, Forenede Stater, 32803
        • Rekruttering
        • AdventHealth Orlando
        • Kontakt:
        • Ledende efterforsker:
          • Fouad M. Hajjar
      • Pensacola, Florida, Forenede Stater, 32504
        • Suspenderet
        • Sacred Heart Hospital
      • Pensacola, Florida, Forenede Stater, 32504
      • St. Petersburg, Florida, Forenede Stater, 33701
        • Rekruttering
        • Johns Hopkins All Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer B. Dean
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • Tampa General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Andrew J. Galligan
      • Tampa, Florida, Forenede Stater, 33607
        • Rekruttering
        • Saint Joseph's Hospital/Children's Hospital-Tampa
        • Kontakt:
        • Ledende efterforsker:
          • Don E. Eslin
      • West Palm Beach, Florida, Forenede Stater, 33407
        • Rekruttering
        • Saint Mary's Medical Center
        • Ledende efterforsker:
          • Matthew D. Ramirez
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 561-822-4745
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital/Winship Cancer Institute
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-778-1868
        • Ledende efterforsker:
          • Pamela B. Allen
      • Atlanta, Georgia, Forenede Stater, 30303
        • Rekruttering
        • Grady Health System
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-778-1868
        • Ledende efterforsker:
          • Pamela B. Allen
      • Atlanta, Georgia, Forenede Stater, 30308
        • Rekruttering
        • Emory University Hospital Midtown
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-946-7447
        • Ledende efterforsker:
          • Pamela B. Allen
      • Atlanta, Georgia, Forenede Stater, 30342
        • Rekruttering
        • Emory Saint Joseph's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-851-7115
        • Ledende efterforsker:
          • Pamela B. Allen
      • Atlanta, Georgia, Forenede Stater, 30308
        • Rekruttering
        • Emory Proton Therapy Center
        • Kontakt:
        • Ledende efterforsker:
          • Pamela B. Allen
      • Atlanta, Georgia, Forenede Stater, 30329
        • Rekruttering
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • Ledende efterforsker:
          • Diana Fridlyand
        • Kontakt:
      • Augusta, Georgia, Forenede Stater, 30912
        • Rekruttering
        • Augusta University Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Colleen H. McDonough
      • Macon, Georgia, Forenede Stater, 31201
        • Rekruttering
        • Atrium Health Navicent
        • Ledende efterforsker:
          • Sushmita Nair
        • Kontakt:
      • Savannah, Georgia, Forenede Stater, 31404
        • Rekruttering
        • Memorial Health University Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • James N. Yarnall
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96826
        • Rekruttering
        • Kapiolani Medical Center for Women and Children
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 808-983-6090
        • Ledende efterforsker:
          • Wade T. Kyono
    • Idaho
      • Boise, Idaho, Forenede Stater, 83712
        • Rekruttering
        • Saint Luke's Cancer Institute - Boise
        • Ledende efterforsker:
          • Martha M. Pacheco
        • Kontakt:
      • Boise, Idaho, Forenede Stater, 83706
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Boise
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Caldwell, Idaho, Forenede Stater, 83605
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Fruitland, Idaho, Forenede Stater, 83619
        • Rekruttering
        • Saint Luke's Cancer Institute - Fruitland
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Meridian, Idaho, Forenede Stater, 83642
        • Rekruttering
        • Idaho Urologic Institute-Meridian
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Meridian, Idaho, Forenede Stater, 83642
        • Rekruttering
        • Saint Luke's Cancer Institute - Meridian
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Nampa, Idaho, Forenede Stater, 83687
        • Rekruttering
        • Saint Luke's Cancer Institute - Nampa
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Nampa, Idaho, Forenede Stater, 83687
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Nampa
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Twin Falls, Idaho, Forenede Stater, 83301
        • Rekruttering
        • Saint Luke's Cancer Institute - Twin Falls
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
    • Illinois
      • Aurora, Illinois, Forenede Stater, 60504
        • Rekruttering
        • Rush-Copley Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Joseph T. Meschi
      • Barrington, Illinois, Forenede Stater, 60010
        • Rekruttering
        • Advocate Good Shepherd Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-842-4847
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Lurie Children's Hospital-Chicago
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 773-880-4562
        • Ledende efterforsker:
          • Joanna L. Weinstein
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Perry C. Morocco
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern University
        • Ledende efterforsker:
          • Jane N. Winter
        • Kontakt:
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • University of Illinois
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 312-355-3046
        • Ledende efterforsker:
          • Dipti S. Dighe
      • Chicago, Illinois, Forenede Stater, 60657
        • Rekruttering
        • Advocate Illinois Masonic Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 773-296-5360
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Chicago, Illinois, Forenede Stater, 60608
        • Rekruttering
        • Mount Sinai Hospital Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 773-257-5960
          • E-mail: suhi@sinai.org
        • Ledende efterforsker:
          • Pam G. Khosla
      • Chicago, Illinois, Forenede Stater, 60625
        • Rekruttering
        • Swedish Covenant Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 773-878-8200
        • Ledende efterforsker:
          • Robert M. Eisner
      • Crystal Lake, Illinois, Forenede Stater, 60014
        • Rekruttering
        • AMG Crystal Lake - Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Danville, Illinois, Forenede Stater, 61832
        • Rekruttering
        • Carle at The Riverfront
        • Ledende efterforsker:
          • Priyank P. Patel
        • Kontakt:
      • DeKalb, Illinois, Forenede Stater, 60115
        • Rekruttering
        • Northwestern Medicine Cancer Center Kishwaukee
        • Ledende efterforsker:
          • Jane N. Winter
        • Kontakt:
      • Decatur, Illinois, Forenede Stater, 62526
        • Rekruttering
        • Decatur Memorial Hospital
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Downers Grove, Illinois, Forenede Stater, 60515
        • Rekruttering
        • Advocate Good Samaritan Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Effingham, Illinois, Forenede Stater, 62401
        • Rekruttering
        • Carle Physician Group-Effingham
        • Kontakt:
        • Ledende efterforsker:
          • Priyank P. Patel
      • Effingham, Illinois, Forenede Stater, 62401
        • Rekruttering
        • Crossroads Cancer Center
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Elgin, Illinois, Forenede Stater, 60123
        • Rekruttering
        • Advocate Sherman Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-429-2907
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Elmhurst, Illinois, Forenede Stater, 60126
        • Rekruttering
        • Elmhurst Memorial Hospital
        • Ledende efterforsker:
          • Joseph Heng
        • Kontakt:
      • Evanston, Illinois, Forenede Stater, 60201
        • Rekruttering
        • NorthShore University HealthSystem-Evanston Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Ledende efterforsker:
          • Robert M. Eisner
      • Geneva, Illinois, Forenede Stater, 60134
        • Rekruttering
        • Northwestern Medicine Cancer Center Delnor
        • Ledende efterforsker:
          • Jane N. Winter
        • Kontakt:
      • Glenview, Illinois, Forenede Stater, 60026
        • Rekruttering
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Ledende efterforsker:
          • Robert M. Eisner
      • Glenview, Illinois, Forenede Stater, 60026
        • Aktiv, ikke rekrutterende
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, Forenede Stater, 60030
        • Aktiv, ikke rekrutterende
        • Northwestern Medicine Grayslake Outpatient Center
      • Hazel Crest, Illinois, Forenede Stater, 60429
        • Rekruttering
        • Advocate South Suburban Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 708-799-9995
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Highland Park, Illinois, Forenede Stater, 60035
        • Rekruttering
        • NorthShore University HealthSystem-Highland Park Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Ledende efterforsker:
          • Robert M. Eisner
      • Lake Forest, Illinois, Forenede Stater, 60045
        • Aktiv, ikke rekrutterende
        • Northwestern Medicine Lake Forest Hospital
      • Libertyville, Illinois, Forenede Stater, 60048
        • Rekruttering
        • AMG Libertyville - Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Libertyville, Illinois, Forenede Stater, 60048
        • Rekruttering
        • Condell Memorial Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Mattoon, Illinois, Forenede Stater, 61938
        • Rekruttering
        • Carle Physician Group-Mattoon/Charleston
        • Kontakt:
        • Ledende efterforsker:
          • Priyank P. Patel
      • Maywood, Illinois, Forenede Stater, 60153
        • Rekruttering
        • Loyola University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 708-226-4357
        • Ledende efterforsker:
          • Eugene Suh
      • Naperville, Illinois, Forenede Stater, 60540
        • Rekruttering
        • Edward Hospital/Cancer Center
        • Ledende efterforsker:
          • Joseph Heng
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 630-646-6075
      • O'Fallon, Illinois, Forenede Stater, 62269
        • Rekruttering
        • HSHS Saint Elizabeth's Hospital
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Oak Lawn, Illinois, Forenede Stater, 60453-2699
        • Rekruttering
        • Advocate Christ Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-323-8622
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Oak Lawn, Illinois, Forenede Stater, 60453
        • Rekruttering
        • Advocate Children's Hospital-Oak Lawn
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-723-7570
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Orland Park, Illinois, Forenede Stater, 60462
      • Park Ridge, Illinois, Forenede Stater, 60068
        • Rekruttering
        • Advocate Lutheran General Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-384-3621
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Park Ridge, Illinois, Forenede Stater, 60068
      • Peoria, Illinois, Forenede Stater, 61637
      • Plainfield, Illinois, Forenede Stater, 60585
        • Rekruttering
        • Edward Hospital/Cancer Center?Plainfield
        • Ledende efterforsker:
          • Joseph Heng
        • Kontakt:
      • Rockford, Illinois, Forenede Stater, 61114
        • Rekruttering
        • UW Health Carbone Cancer Center Rockford
        • Kontakt:
        • Ledende efterforsker:
          • Fahrettin Covut
      • Shiloh, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Memorial Hospital East
        • Kontakt:
        • Ledende efterforsker:
          • Nancy L. Bartlett
      • Springfield, Illinois, Forenede Stater, 62702
        • Rekruttering
        • Southern Illinois University School of Medicine
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 217-545-7929
        • Ledende efterforsker:
          • Gregory P. Brandt
      • Urbana, Illinois, Forenede Stater, 61801
        • Rekruttering
        • Carle Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Priyank P. Patel
      • Warrenville, Illinois, Forenede Stater, 60555
        • Rekruttering
        • Northwestern Medicine Cancer Center Warrenville
        • Ledende efterforsker:
          • Jane N. Winter
        • Kontakt:
      • Yorkville, Illinois, Forenede Stater, 60560
        • Suspenderet
        • Rush-Copley Healthcare Center
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • Riley Hospital for Children
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-248-1199
        • Ledende efterforsker:
          • Jennifer A. Belsky
      • Indianapolis, Indiana, Forenede Stater, 46260
        • Rekruttering
        • Ascension Saint Vincent Indianapolis Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Bassem I. Razzouk
    • Iowa
      • Ankeny, Iowa, Forenede Stater, 50023
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Carroll, Iowa, Forenede Stater, 51401
        • Rekruttering
        • Saint Anthony Regional Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Clive, Iowa, Forenede Stater, 50325
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50309
        • Rekruttering
        • Blank Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Samantha L. Mallory
      • Des Moines, Iowa, Forenede Stater, 50309
        • Rekruttering
        • Iowa Methodist Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-6727
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50309
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50314
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
        • Ledende efterforsker:
          • Andrew P. Groves
      • Waukee, Iowa, Forenede Stater, 50263
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
    • Kansas
      • Wichita, Kansas, Forenede Stater, 67214
        • Rekruttering
        • Wesley Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Nathan S. Hall
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • Rekruttering
        • University of Kentucky/Markey Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
        • Ledende efterforsker:
          • James T. Badgett
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • Norton Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Michael J. Ferguson
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • The James Graham Brown Cancer Center at University of Louisville
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 502-562-3429
        • Ledende efterforsker:
          • Hassaan Yasin
      • Louisville, Kentucky, Forenede Stater, 40245
        • Rekruttering
        • UofL Health Medical Center Northeast
        • Kontakt:
        • Ledende efterforsker:
          • Hassaan Yasin
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70118
        • Rekruttering
        • Children's Hospital New Orleans
        • Ledende efterforsker:
          • Maria C. Velez-Yanguas
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 504-894-5377
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Rekruttering
        • Ochsner Medical Center Jefferson
        • Kontakt:
        • Ledende efterforsker:
          • Craig Lotterman
    • Maine
      • Bangor, Maine, Forenede Stater, 04401
        • Rekruttering
        • Eastern Maine Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 207-973-4274
        • Ledende efterforsker:
          • Daniel L. Callaway
      • Bath, Maine, Forenede Stater, 04530
        • Rekruttering
        • MaineHealth Coastal Cancer Treatment Center
        • Kontakt:
        • Ledende efterforsker:
          • Nadav L. Kastle
      • Portland, Maine, Forenede Stater, 04102
        • Rekruttering
        • MaineHealth Maine Medical Center - Portland
        • Ledende efterforsker:
          • Nadav L. Kastle
        • Kontakt:
      • Sanford, Maine, Forenede Stater, 04073
        • Rekruttering
        • MaineHealth Cancer Care Center of York County
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 207-459-1600
        • Ledende efterforsker:
          • Nadav L. Kastle
      • Scarborough, Maine, Forenede Stater, 04074
        • Rekruttering
        • Maine Children's Cancer Program
        • Ledende efterforsker:
          • Nadav L. Kastle
        • Kontakt:
      • Scarborough, Maine, Forenede Stater, 04074
        • Rekruttering
        • MaineHealth Maine Medical Center- Scarborough
        • Ledende efterforsker:
          • Nadav L. Kastle
        • Kontakt:
      • South Portland, Maine, Forenede Stater, 04106
        • Rekruttering
        • MaineHealth Cancer Care and IV Therapy - South Portland
        • Ledende efterforsker:
          • Nadav L. Kastle
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Rekruttering
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Ledende efterforsker:
          • Stacy L. Cooper
        • Kontakt:
      • Baltimore, Maryland, Forenede Stater, 21215
        • Rekruttering
        • Sinai Hospital of Baltimore
        • Ledende efterforsker:
          • Jason M. Fixler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 410-601-9083
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland/Greenebaum Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-888-8823
        • Ledende efterforsker:
          • Teresa A. York
      • Bethesda, Maryland, Forenede Stater, 20889-5600
        • Rekruttering
        • Walter Reed National Military Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 301-319-2100
        • Ledende efterforsker:
          • Kip R. Hartman
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Dana-Farber Cancer Institute
        • Ledende efterforsker:
          • Ann S. LaCasce
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-442-3324
      • Worcester, Massachusetts, Forenede Stater, 01655
        • Rekruttering
        • UMass Memorial Medical Center - University Campus
        • Kontakt:
        • Ledende efterforsker:
          • Stefanie R. Lowas
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • C S Mott Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-865-1125
        • Ledende efterforsker:
          • Emily B. Walling
      • Ann Arbor, Michigan, Forenede Stater, 48106
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Battle Creek, Michigan, Forenede Stater, 49017
        • Rekruttering
        • Bronson Battle Creek
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Brighton, Michigan, Forenede Stater, 48114
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Brownstown, Michigan, Forenede Stater, 48183
        • Rekruttering
        • Henry Ford Cancer Institute-Downriver
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Canton, Michigan, Forenede Stater, 48188
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Chelsea, Michigan, Forenede Stater, 48118
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Clinton Township, Michigan, Forenede Stater, 48038
        • Rekruttering
        • Henry Ford Macomb Hospital-Clinton Township
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Dearborn, Michigan, Forenede Stater, 48126
        • Rekruttering
        • Henry Ford Medical Center-Fairlane
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Dearborn, Michigan, Forenede Stater, 48124
        • Rekruttering
        • Corewell Health Dearborn Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Marie V. Nelson
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Wayne State University/Karmanos Cancer Institute
        • Ledende efterforsker:
          • Vijendra Singh
        • Kontakt:
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Detroit, Michigan, Forenede Stater, 48201
      • East Lansing, Michigan, Forenede Stater, 48823
        • Aktiv, ikke rekrutterende
        • Michigan State University
      • Farmington Hills, Michigan, Forenede Stater, 48334
        • Rekruttering
        • Weisberg Cancer Treatment Center
        • Kontakt:
        • Ledende efterforsker:
          • Vijendra Singh
      • Farmington Hills, Michigan, Forenede Stater, 48336
        • Rekruttering
        • Corewell Health Farmington Hills Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Marie V. Nelson
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Rekruttering
        • Trinity Health Grand Rapids Hospital
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Rekruttering
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Rekruttering
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Jackson, Michigan, Forenede Stater, 49201
        • Rekruttering
        • Allegiance Health
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Kalamazoo, Michigan, Forenede Stater, 49007
        • Rekruttering
        • Bronson Methodist Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Forenede Stater, 49007
        • Rekruttering
        • West Michigan Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Forenede Stater, 49009
        • Rekruttering
        • Beacon Kalamazoo Cancer Center
        • Ledende efterforsker:
          • Kathleen Y. Butler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 574-647-7370
      • Livonia, Michigan, Forenede Stater, 48154
        • Rekruttering
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Macomb, Michigan, Forenede Stater, 48044
        • Rekruttering
        • Henry Ford Saint John Hospital - Macomb Medical
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Muskegon, Michigan, Forenede Stater, 49444
        • Suspenderet
        • Trinity Health Muskegon Hospital
      • Norton Shores, Michigan, Forenede Stater, 49444
        • Rekruttering
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Novi, Michigan, Forenede Stater, 48377
        • Rekruttering
        • Henry Ford Medical Center-Columbus
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Novi, Michigan, Forenede Stater, 48374
        • Suspenderet
        • Henry Ford Health Providence Novi Hospital
      • Pontiac, Michigan, Forenede Stater, 48341
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Reed City, Michigan, Forenede Stater, 49677
        • Rekruttering
        • Corewell Health Reed City Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, Forenede Stater, 48073
        • Rekruttering
        • Corewell Health William Beaumont University Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Marie V. Nelson
      • Royal Oak, Michigan, Forenede Stater, 48073
        • Rekruttering
        • Corewell Health Children's
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Marie V. Nelson
      • Saint Joseph, Michigan, Forenede Stater, 49085
        • Rekruttering
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Southfield, Michigan, Forenede Stater, 48075
        • Suspenderet
        • Henry Ford Health Providence Southfield Hospital
      • Traverse City, Michigan, Forenede Stater, 49684
        • Rekruttering
        • Munson Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Troy, Michigan, Forenede Stater, 48085
        • Rekruttering
        • Corewell Health Beaumont Troy Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Marie V. Nelson
      • West Bloomfield, Michigan, Forenede Stater, 48322
        • Rekruttering
        • Henry Ford West Bloomfield Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Wyandotte, Michigan, Forenede Stater, 48192
        • Rekruttering
        • Henry Ford Wyandotte Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Philip Kuriakose
      • Wyoming, Michigan, Forenede Stater, 49519
        • Rekruttering
        • University of Michigan Health - West
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, Forenede Stater, 48197
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
    • Minnesota
      • Coon Rapids, Minnesota, Forenede Stater, 55433
        • Rekruttering
        • Mercy Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Edina, Minnesota, Forenede Stater, 55435
        • Rekruttering
        • Fairview Southdale Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Edina, Minnesota, Forenede Stater, 55435
        • Rekruttering
        • Minnesota Oncology - Edina
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Minneapolis, Minnesota, Forenede Stater, 55404
        • Rekruttering
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • Ledende efterforsker:
          • Michael K. Richards
        • Kontakt:
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Rekruttering
        • Abbott-Northwestern Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • University of Minnesota/Masonic Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 612-624-2620
        • Ledende efterforsker:
          • Peter M. Gordon
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Ledende efterforsker:
          • Mira Kohorst
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
      • Saint Louis Park, Minnesota, Forenede Stater, 55416
        • Rekruttering
        • Park Nicollet Clinic - Saint Louis Park
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forenede Stater, 55101
        • Rekruttering
        • Regions Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forenede Stater, 55102
        • Rekruttering
        • United Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
      • Woodbury, Minnesota, Forenede Stater, 55125
        • Rekruttering
        • Minnesota Oncology Hematology PA-Woodbury
        • Kontakt:
        • Ledende efterforsker:
          • David M. King
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39216
        • Rekruttering
        • University of Mississippi Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 601-815-6700
        • Ledende efterforsker:
          • Amanda Strobel
    • Missouri
      • Cape Girardeau, Missouri, Forenede Stater, 63703
        • Rekruttering
        • Saint Francis Medical Center
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 573-334-2230
          • E-mail: sfmc@sfmc.net
      • Chesterfield, Missouri, Forenede Stater, 63017
        • Rekruttering
        • Saint Luke's Hospital
        • Ledende efterforsker:
          • Mark J. Fesler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-205-6936
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Rekruttering
        • Siteman Cancer Center at Saint Peters Hospital
        • Ledende efterforsker:
          • Nancy L. Bartlett
        • Kontakt:
      • Columbia, Missouri, Forenede Stater, 65212
        • Rekruttering
        • University of Missouri Children's Hospital
        • Ledende efterforsker:
          • Barbara A. Gruner
        • Kontakt:
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Rekruttering
        • Siteman Cancer Center at West County Hospital
        • Ledende efterforsker:
          • Nancy L. Bartlett
        • Kontakt:
      • Kansas City, Missouri, Forenede Stater, 64108
        • Rekruttering
        • Children's Mercy Hospitals and Clinics
        • Ledende efterforsker:
          • Keith J. August
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Ledende efterforsker:
          • Nancy L. Bartlett
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63141
        • Rekruttering
        • Mercy Hospital Saint Louis
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-251-7066
        • Ledende efterforsker:
          • Robin D. Hanson
      • St Louis, Missouri, Forenede Stater, 63104
        • Rekruttering
        • Cardinal Glennon Children's Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-268-4000
        • Ledende efterforsker:
          • William S. Ferguson
      • St Louis, Missouri, Forenede Stater, 63129
        • Rekruttering
        • Siteman Cancer Center-South County
        • Ledende efterforsker:
          • Nancy L. Bartlett
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63136
        • Rekruttering
        • Siteman Cancer Center at Christian Hospital
        • Ledende efterforsker:
          • Nancy L. Bartlett
        • Kontakt:
    • Nebraska
      • Bellevue, Nebraska, Forenede Stater, 68123
        • Rekruttering
        • Nebraska Medicine-Bellevue
        • Kontakt:
        • Ledende efterforsker:
          • Jill C. Beck
      • Omaha, Nebraska, Forenede Stater, 68114
        • Rekruttering
        • Children's Hospital and Medical Center of Omaha
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-955-3949
        • Ledende efterforsker:
          • Jill C. Beck
      • Omaha, Nebraska, Forenede Stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jill C. Beck
      • Omaha, Nebraska, Forenede Stater, 68118
        • Rekruttering
        • Nebraska Medicine-Village Pointe
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-559-5600
        • Ledende efterforsker:
          • Jill C. Beck
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89135
        • Rekruttering
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
        • Kontakt:
        • Ledende efterforsker:
          • Joseph L. Lasky
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
        • Ledende efterforsker:
          • Seema L. Rao
        • Kontakt:
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03756
        • Rekruttering
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Ledende efterforsker:
          • Angela Ricci
        • Kontakt:
    • New Jersey
      • Camden, New Jersey, Forenede Stater, 08103
        • Rekruttering
        • Cooper Hospital University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 856-325-6757
        • Ledende efterforsker:
          • Sushil Ghimire
      • Elizabeth, New Jersey, Forenede Stater, 07207
        • Rekruttering
        • Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 908-994-8000
        • Ledende efterforsker:
          • Richard A. Drachtman
      • Flemington, New Jersey, Forenede Stater, 08822
        • Rekruttering
        • Hunterdon Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 908-237-2330
        • Ledende efterforsker:
          • Myron E. Bednar
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Rekruttering
        • Hackensack University Medical Center
        • Ledende efterforsker:
          • Burton E. Appel
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 551-996-2897
      • Jersey City, New Jersey, Forenede Stater, 07302
        • Rekruttering
        • Jersey City Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Richard A. Drachtman
      • Livingston, New Jersey, Forenede Stater, 07039
        • Rekruttering
        • Cooperman Barnabas Medical Center
        • Ledende efterforsker:
          • Richard A. Drachtman
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 973-322-5200
      • Long Branch, New Jersey, Forenede Stater, 07740
        • Rekruttering
        • Monmouth Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Richard A. Drachtman
      • Morristown, New Jersey, Forenede Stater, 07960
        • Rekruttering
        • Morristown Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 973-971-5900
        • Ledende efterforsker:
          • Kathryn L. Laurie
      • Neptune City, New Jersey, Forenede Stater, 07753
        • Rekruttering
        • Jersey Shore Medical Center
        • Ledende efterforsker:
          • Burton E. Appel
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 732-776-4240
      • New Brunswick, New Jersey, Forenede Stater, 08903
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 732-235-7356
        • Ledende efterforsker:
          • Richard A. Drachtman
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rekruttering
        • Saint Peter's University Hospital
        • Ledende efterforsker:
          • Nibal A. Zaghloul
        • Kontakt:
      • New Brunswick, New Jersey, Forenede Stater, 08903
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 732-235-8675
        • Ledende efterforsker:
          • Richard A. Drachtman
      • Newark, New Jersey, Forenede Stater, 07112
        • Rekruttering
        • Newark Beth Israel Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Teena Bhatla
      • Paterson, New Jersey, Forenede Stater, 07503
        • Rekruttering
        • Saint Joseph's Regional Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Alissa Kahn
      • Toms River, New Jersey, Forenede Stater, 08755
        • Rekruttering
        • Community Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Richard A. Drachtman
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • Rekruttering
        • Presbyterian Hospital
        • Ledende efterforsker:
          • Beeling Armijo
        • Kontakt:
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • Suspenderet
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Forenede Stater, 12208
        • Rekruttering
        • Albany Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 518-262-5513
        • Ledende efterforsker:
          • Lauren R. Weintraub
      • Buffalo, New York, Forenede Stater, 14263
        • Rekruttering
        • Roswell Park Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Kara M. Kelly
      • Camillus, New York, Forenede Stater, 13031
        • Rekruttering
        • Hematology Oncology Associates of CNY at Camillus
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-472-7504
        • Ledende efterforsker:
          • Steven M. Duffy
      • East Syracuse, New York, Forenede Stater, 13057
        • Rekruttering
        • Hematology Oncology Associates of Central New York-East Syracuse
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-472-7504
        • Ledende efterforsker:
          • Steven M. Duffy
      • Glens Falls, New York, Forenede Stater, 12801
        • Aktiv, ikke rekrutterende
        • Glens Falls Hospital
      • Mineola, New York, Forenede Stater, 11501
        • Rekruttering
        • NYU Langone Hospital - Long Island
        • Kontakt:
        • Ledende efterforsker:
          • Chana L. Glasser
      • New Hyde Park, New York, Forenede Stater, 11040
        • Rekruttering
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 718-470-3460
        • Ledende efterforsker:
          • Arlene S. Redner
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Ledende efterforsker:
          • Nobuko Hijiya
        • Kontakt:
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Ledende efterforsker:
          • Christopher J. Forlenza
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Ledende efterforsker:
          • Elizabeth A. Raetz
        • Kontakt:
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Mount Sinai Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-mail: CCTO@mssm.edu
        • Ledende efterforsker:
          • Pamela R. Merola
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • NYP/Weill Cornell Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-746-1848
        • Ledende efterforsker:
          • Nitya Gulati
      • Rochester, New York, Forenede Stater, 14642
        • Rekruttering
        • University of Rochester
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 585-275-5830
        • Ledende efterforsker:
          • Carla Casulo
      • Stony Brook, New York, Forenede Stater, 11794
        • Rekruttering
        • Stony Brook University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-862-2215
        • Ledende efterforsker:
          • Laura E. Hogan
      • Syracuse, New York, Forenede Stater, 13210
        • Rekruttering
        • State University of New York Upstate Medical University
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-464-5476
        • Ledende efterforsker:
          • Melanie A. Comito
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Montefiore Medical Center - Moses Campus
        • Kontakt:
        • Ledende efterforsker:
          • Alice Lee
      • Webster, New York, Forenede Stater, 14580
      • Williamsville, New York, Forenede Stater, 14221
        • Rekruttering
        • Roswell Park Amherst Center
        • Kontakt:
        • Ledende efterforsker:
          • Kara M. Kelly
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 28801
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • UNC Lineberger Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Natalie S. Grover
      • Charlotte, North Carolina, Forenede Stater, 28203
        • Rekruttering
        • Carolinas Medical Center/Levine Cancer Institute
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-804-9376
        • Ledende efterforsker:
          • Joel A. Kaplan
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Rekruttering
        • Novant Health Presbyterian Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Holly Edington
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Ledende efterforsker:
          • Jessica M. Sun
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
      • Greenville, North Carolina, Forenede Stater, 27834
        • Rekruttering
        • East Carolina University
        • Kontakt:
        • Ledende efterforsker:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Rekruttering
        • Wake Forest University Health Sciences
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 336-713-6771
        • Ledende efterforsker:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, Forenede Stater, 58122
    • Ohio
      • Akron, Ohio, Forenede Stater, 44308
        • Rekruttering
        • Children's Hospital Medical Center of Akron
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 330-543-3193
        • Ledende efterforsker:
          • Lauren R. Draper
      • Cincinnati, Ohio, Forenede Stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Robin E. Norris
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic Foundation
        • Kontakt:
        • Ledende efterforsker:
          • Matteo M. Trucco
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • Rainbow Babies and Childrens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 216-844-5437
        • Ledende efterforsker:
          • Duncan S. Stearns
      • Columbus, Ohio, Forenede Stater, 43205
      • Dayton, Ohio, Forenede Stater, 45404
        • Rekruttering
        • Dayton Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-228-4055
        • Ledende efterforsker:
          • Jordan M. Wright
      • Toledo, Ohio, Forenede Stater, 43606
        • Rekruttering
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jamie L. Dargart
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Ledende efterforsker:
          • Rene Y. McNall-Knapp
      • Tulsa, Oklahoma, Forenede Stater, 74136
        • Rekruttering
        • Saint Francis Children's Hospital
        • Ledende efterforsker:
          • Jill A. Salo
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 918-502-6720
    • Oregon
      • Baker City, Oregon, Forenede Stater, 97814
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Baker City
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Newberg, Oregon, Forenede Stater, 97132
        • Rekruttering
        • Providence Newberg Medical Center
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Ontario, Oregon, Forenede Stater, 97914
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Ontario
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Oregon City, Oregon, Forenede Stater, 97045
        • Rekruttering
        • Providence Willamette Falls Medical Center
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Portland, Oregon, Forenede Stater, 97227
        • Rekruttering
        • Legacy Emanuel Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 503-413-2560
        • Ledende efterforsker:
          • Jason M. Glover
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Oregon Health and Science University
        • Kontakt:
        • Ledende efterforsker:
          • Bill H. Chang
      • Portland, Oregon, Forenede Stater, 97213
        • Rekruttering
        • Providence Portland Medical Center
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
      • Portland, Oregon, Forenede Stater, 97225
        • Rekruttering
        • Providence Saint Vincent Medical Center
        • Ledende efterforsker:
          • Dan S. Zuckerman
        • Kontakt:
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
        • Rekruttering
        • Lehigh Valley Hospital-Cedar Crest
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Danville, Pennsylvania, Forenede Stater, 17822
        • Rekruttering
        • Geisinger Medical Center
        • Ledende efterforsker:
          • Jagadeesh Ramdas
        • Kontakt:
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Rekruttering
        • Penn State Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 717-531-6012
        • Ledende efterforsker:
          • Lisa M. McGregor
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Kontakt:
        • Ledende efterforsker:
          • Leslie S. Kersun
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Rekruttering
        • Thomas Jefferson University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Michael Wysota
      • Philadelphia, Pennsylvania, Forenede Stater, 19134
        • Rekruttering
        • Saint Christopher's Hospital for Children
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 215-427-8991
        • Ledende efterforsker:
          • Gregory E. Halligan
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Rekruttering
        • Children's Hospital of Pittsburgh of UPMC
        • Kontakt:
        • Ledende efterforsker:
          • Jean M. Tersak
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
        • Rekruttering
        • Rhode Island Hospital
        • Ledende efterforsker:
          • Bradley DeNardo
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 401-444-1488
      • Westerly, Rhode Island, Forenede Stater, 02891
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Westerly
        • Kontakt:
        • Ledende efterforsker:
          • Farzana Pashankar
    • South Carolina
      • Boiling Springs, South Carolina, Forenede Stater, 29316
        • Rekruttering
        • Prisma Health Cancer Institute - Spartanburg
        • Ledende efterforsker:
          • Aniket Saha
        • Kontakt:
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Kontakt:
        • Ledende efterforsker:
          • Jacqueline M. Kraveka
      • Columbia, South Carolina, Forenede Stater, 29203
        • Rekruttering
        • Prisma Health Richland Hospital
        • Ledende efterforsker:
          • Stuart L. Cramer
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • BI-LO Charities Children's Cancer Center
        • Ledende efterforsker:
          • Aniket Saha
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29601
        • Rekruttering
        • Saint Francis Hospital
        • Ledende efterforsker:
          • Stephen H. Dyar
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29607
        • Rekruttering
        • Saint Francis Cancer Center
        • Ledende efterforsker:
          • Stephen H. Dyar
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29615
        • Rekruttering
        • Prisma Health Cancer Institute - Eastside
        • Ledende efterforsker:
          • Aniket Saha
        • Kontakt:
      • Seneca, South Carolina, Forenede Stater, 29672
        • Rekruttering
        • Prisma Health Cancer Institute - Seneca
        • Ledende efterforsker:
          • Aniket Saha
        • Kontakt:
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57117-5134
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37403
        • Rekruttering
        • T C Thompson Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 423-778-7289
        • Ledende efterforsker:
          • Benjamin A. Mixon
      • Knoxville, Tennessee, Forenede Stater, 37916
        • Rekruttering
        • East Tennessee Childrens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 865-541-8266
        • Ledende efterforsker:
          • Susan E. Spiller
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University/Ingram Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-811-8480
        • Ledende efterforsker:
          • Christine M. Smith
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • The Children's Hospital at TriStar Centennial
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 615-342-1919
        • Ledende efterforsker:
          • Clinton M. Carroll
    • Texas
      • Austin, Texas, Forenede Stater, 78723
        • Rekruttering
        • Dell Children's Medical Center of Central Texas
        • Kontakt:
        • Ledende efterforsker:
          • Shannon M. Cohn
      • Corpus Christi, Texas, Forenede Stater, 78411
        • Rekruttering
        • Driscoll Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Nkechi I. Mba
      • Dallas, Texas, Forenede Stater, 75390
        • Rekruttering
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Ledende efterforsker:
          • Ksenya Shliakhtsitsava
        • Kontakt:
      • Dallas, Texas, Forenede Stater, 75230
        • Rekruttering
        • Medical City Dallas Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 972-566-5588
        • Ledende efterforsker:
          • Maurizio L. Ghisoli
      • El Paso, Texas, Forenede Stater, 79905
        • Rekruttering
        • El Paso Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Benjamin Carcamo
      • Fort Worth, Texas, Forenede Stater, 76104
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 713-798-1354
          • E-mail: burton@bcm.edu
        • Ledende efterforsker:
          • Kala Y. Kamdar
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • UT MD Anderson Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Najat C. Daw
      • Lubbock, Texas, Forenede Stater, 79410
        • Rekruttering
        • Covenant Children's Hospital
        • Ledende efterforsker:
          • Kishor M. Bhende
        • Kontakt:
      • Lubbock, Texas, Forenede Stater, 79415
        • Rekruttering
        • UMC Cancer Center / UMC Health System
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 806-775-8590
        • Ledende efterforsker:
          • Erin K. Barr
      • San Antonio, Texas, Forenede Stater, 78207
        • Rekruttering
        • Children's Hospital of San Antonio
        • Kontakt:
        • Ledende efterforsker:
          • Julie Voeller
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • University of Texas Health Science Center at San Antonio
        • Kontakt:
        • Ledende efterforsker:
          • Allison C. Grimes
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • Methodist Children's Hospital of South Texas
        • Kontakt:
        • Ledende efterforsker:
          • Jose M. Esquilin
      • Temple, Texas, Forenede Stater, 76508
        • Rekruttering
        • Scott and White Memorial Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 254-724-5407
        • Ledende efterforsker:
          • Nicholas W. McGregor
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84113
        • Rekruttering
        • Primary Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 801-585-5270
        • Ledende efterforsker:
          • Mallorie B. Heneghan
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • Huntsman Cancer Institute/University of Utah
        • Ledende efterforsker:
          • Boyu Hu
        • Kontakt:
    • Vermont
      • Burlington, Vermont, Forenede Stater, 05405
        • Rekruttering
        • University of Vermont and State Agricultural College
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 802-656-8990
          • E-mail: rpo@uvm.edu
        • Ledende efterforsker:
          • Jessica L. Heath
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
      • Falls Church, Virginia, Forenede Stater, 22042
        • Rekruttering
        • Inova Fairfax Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Robin Y. Dulman
      • Norfolk, Virginia, Forenede Stater, 23507
        • Rekruttering
        • Children's Hospital of The King's Daughters
        • Kontakt:
        • Ledende efterforsker:
          • Melissa S. Mark
      • Portsmouth, Virginia, Forenede Stater, 23708-2197
        • Rekruttering
        • Naval Medical Center - Portsmouth
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 757-953-5939
        • Ledende efterforsker:
          • Karin Brockman
      • Richmond, Virginia, Forenede Stater, 23298
        • Rekruttering
        • VCU Massey Comprehensive Cancer Center
        • Ledende efterforsker:
          • Jordyn R. Griffin
        • Kontakt:
      • Roanoke, Virginia, Forenede Stater, 24014
        • Rekruttering
        • Carilion Children's
        • Kontakt:
        • Ledende efterforsker:
          • Erwood G. Edwards
    • Washington
      • Renton, Washington, Forenede Stater, 98055
        • Suspenderet
        • Valley Medical Center
      • Seattle, Washington, Forenede Stater, 98105
        • Rekruttering
        • Seattle Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 866-987-2000
        • Ledende efterforsker:
          • Sarah E. Leary
      • Spokane, Washington, Forenede Stater, 99204
        • Rekruttering
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Judy L. Felgenhauer
      • Tacoma, Washington, Forenede Stater, 98405
        • Rekruttering
        • Mary Bridge Children's Hospital and Health Center
        • Kontakt:
        • Ledende efterforsker:
          • Robert G. Irwin
    • West Virginia
      • Charleston, West Virginia, Forenede Stater, 25304
        • Rekruttering
        • Vandalia Health/CAMC Institute for Academic Medicine
        • Ledende efterforsker:
          • Mohamad H. Badawi
        • Kontakt:
      • Huntington, West Virginia, Forenede Stater, 25701
        • Rekruttering
        • Edwards Comprehensive Cancer Center
        • Ledende efterforsker:
          • Mark A. Ranalli
        • Kontakt:
    • Wisconsin
      • Burlington, Wisconsin, Forenede Stater, 53105
        • Rekruttering
        • Aurora Cancer Care-Southern Lakes VLCC
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Cudahy, Wisconsin, Forenede Stater, 53110
        • Rekruttering
        • Aurora Saint Luke's South Shore
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Germantown, Wisconsin, Forenede Stater, 53022
        • Rekruttering
        • Aurora Health Care Germantown Health Center
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Grafton, Wisconsin, Forenede Stater, 53024
        • Rekruttering
        • Aurora Cancer Care-Grafton
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Green Bay, Wisconsin, Forenede Stater, 54311
        • Rekruttering
        • Aurora BayCare Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Green Bay, Wisconsin, Forenede Stater, 54301
        • Rekruttering
        • Saint Vincent Hospital Cancer Center Green Bay
        • Ledende efterforsker:
          • Catherine A. Long
        • Kontakt:
      • Kenosha, Wisconsin, Forenede Stater, 53142
        • Rekruttering
        • Aurora Cancer Care-Kenosha South
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • La Crosse, Wisconsin, Forenede Stater, 54601
        • Rekruttering
        • Gundersen Lutheran Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kurt Oettel
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Ledende efterforsker:
          • Priyanka Pophali
        • Kontakt:
      • Madison, Wisconsin, Forenede Stater, 53718
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Ledende efterforsker:
          • Priyanka Pophali
        • Kontakt:
      • Marinette, Wisconsin, Forenede Stater, 54143
        • Rekruttering
        • Aurora Bay Area Medical Group-Marinette
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Marshfield, Wisconsin, Forenede Stater, 54449
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Children's Hospital of Wisconsin
        • Kontakt:
        • Ledende efterforsker:
          • Michael J. Burke
      • Milwaukee, Wisconsin, Forenede Stater, 53209
        • Rekruttering
        • Aurora Cancer Care-Milwaukee
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Rekruttering
        • Aurora Saint Luke's Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Milwaukee, Wisconsin, Forenede Stater, 53233
        • Rekruttering
        • Aurora Sinai Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Mukwonago, Wisconsin, Forenede Stater, 53149
        • Rekruttering
        • ProHealth D N Greenwald Center
        • Kontakt:
        • Ledende efterforsker:
          • Timothy R. Wassenaar
      • Oconomowoc, Wisconsin, Forenede Stater, 53066
        • Rekruttering
        • ProHealth Oconomowoc Memorial Hospital
        • Ledende efterforsker:
          • Timothy R. Wassenaar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 262-928-7878
      • Oshkosh, Wisconsin, Forenede Stater, 54904
        • Rekruttering
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Racine, Wisconsin, Forenede Stater, 53406
        • Rekruttering
        • Aurora Cancer Care-Racine
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Sheboygan, Wisconsin, Forenede Stater, 53081
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Sheboygan
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Sheboygan, Wisconsin, Forenede Stater, 53081
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Sheboygan
        • Ledende efterforsker:
          • Catherine A. Long
        • Kontakt:
      • Sturgeon Bay, Wisconsin, Forenede Stater, 54235-1495
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
        • Ledende efterforsker:
          • Catherine A. Long
        • Kontakt:
      • Summit, Wisconsin, Forenede Stater, 53066
        • Rekruttering
        • Aurora Medical Center in Summit
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Two Rivers, Wisconsin, Forenede Stater, 54241
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Two Rivers
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • Waukesha, Wisconsin, Forenede Stater, 53188
        • Rekruttering
        • UW Cancer Center at ProHealth Care
        • Ledende efterforsker:
          • Timothy R. Wassenaar
        • Kontakt:
      • Wauwatosa, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Aurora Cancer Care-Milwaukee West
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • West Allis, Wisconsin, Forenede Stater, 53227
        • Rekruttering
        • Aurora West Allis Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca E. McFall
      • San Juan, Puerto Rico, 00926
        • Rekruttering
        • University Pediatric Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 787-474-0333
        • Ledende efterforsker:
          • Maria E. Echevarria

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

5 år til 60 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients must be 5 to 60 years of age at the time of enrollment

  • Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]) with stage I or II disease

  • Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm)

  • Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained

  • Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.

    • Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
  • Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2

  • Patients =< 17 years of age must have a Lansky performance score of >= 50

  • Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment):

    • 2 to < 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
    • 6 to < 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
    • 10 to < 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
    • 13 to < 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
    • >= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight

  • Total bilirubin =< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Aspartate aminotransferase (AST) =< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Alanine aminotransferase (ALT) =< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)

  • Diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of > 92% on room air

  • Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Patients with nodular lymphocyte predominant Hodgkin lymphoma

  • Patients with a history of active interstitial pneumonitis or interstitial lung disease

  • Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients

  • Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills

  • Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to > 10 mg daily predniSONE for patients >= 18 years or > 0.5 mg/kg [up to 10 mg/day] for patients < 18 years) or other immunosuppressive medications within 14 days prior to enrollment

    • Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=< 10 mg daily for patients >= 18 years or =< 0.5 mg/kg [up to 10 mg/day] predniSONE equivalents) are permitted in the absence of active autoimmune disease
    • Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
    • Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids.
  • Patients with peripheral neuropathy > grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome

  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen

  • Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL

  • Prior solid organ transplant

  • Prior allogeneic stem cell transplantation

  • Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin [BCG], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted

  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential

  • Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment

  • Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer

    • Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin
    • WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab
  • All patients and/or their parents or legal guardians must sign a written informed consent

  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Arm A (ABVD)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)
Eksperimentel: Arm B (ABVD, brentuximab vedotin, nivolumab)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 antistof-lægemiddelkonjugat SGN-35
  • Anti-CD30 monoklonalt antistof-MMAE SGN-35
  • Anti-CD30 Monoklonalt Antistof-Monomethylauristatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Andre navne:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)
Eksperimentel: Arm C (ABVD, eBEACOPP or eBPDac, ISRT)

See Detailed Description.

Given IV

Andre navne:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamid
  • 2H-1,3,2-Oxazaphosphorin, 2-[bis(2-chlorethyl)amino]tetrahydro-, 2-oxid, monohydrat
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamid
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrat
  • CYCLO-celle
  • Cykloblastin
  • Cycloblastin
  • Cyclofosfam
  • Cyclophosphamid monohydrat
  • Cyclophosphamid Monohydrat
  • Cyclophospamidum
  • Cyclofosfan
  • Cyclophosphanum
  • Cyclostin
  • Cytophosphan
  • Cytofosfan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimune
  • Syklofosfamid
  • WR- 138719
  • Asta B 518
  • B-518
  • WR-138719
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Given PO

Andre navne:
  • Deltasone
  • Orasone
  • 81-kortison
  • 1,2-dehydrocortison
  • Adasone
  • Cortancyl
  • Dacortin
  • DeCortin
  • Decortisyl
  • Decorton
  • Delta 1-kortison
  • Delta-Dome
  • Deltacortene
  • Deltacortison
  • Deltadehydrocortison
  • Deltison
  • Delta
  • Econosone
  • Lisacort
  • Meprosona-F
  • Metacortandracin
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracort
  • Perrigo Prednison
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Predniment
  • Prednison Intensol
  • Prednisonum
  • Predniton
  • Promifen
  • Rayos
  • Servisone
  • SK-Prednison

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Given IV

Andre navne:
  • Oncovin
  • Kyocristine
  • Leurocristinsulfat
  • Leurocristin, sulfat
  • Vincasar
  • Vincosid
  • Vincrex
  • Vincristin, sulfat

Ancillary studies

Given IV

Andre navne:
  • Demethyl Epipodophyllotoxin Ethylidin Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given IV

Andre navne:
  • Etopophos

Given PO

Andre navne:
  • (11beta)-11,17,21-Trihydroxypregna-1,4-dien-3,20-dion
  • 61-Hydrocortison
  • Adnisolon
  • Aprednislon
  • Kapsoid
  • Cortalone
  • Kortisolon
  • Dacortin H
  • Decaprednil
  • Decortin H
  • Delta(1)Hydrocortison
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-Phoricol
  • Delta1-dehydro-hydrocortison
  • Deltacortril
  • Deltahydrocortison
  • Deltasolone
  • Deltidrosol
  • Dhasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolon
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralon
  • Meti Derm
  • Meticortelone
  • Opredsone
  • Panafcortelone
  • Precortisyl
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolum
  • Prelone
  • Prenilon
  • Sterane

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)

Undergo ISRT

Andre navne:
  • ISRT

Given PO

Andre navne:
  • PCZ
  • Matulane
  • PCB
  • Natulanar
  • Benzamid, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-, monohydrochlorid (9Cl)
  • Ibenzmethyzinhydrochlorid
  • MIH hydrochlorid
  • Natulan
  • Naturalar
  • NCI-C01810
  • p-(N'-methylhydrazinomethyl)-N-isopropylbenzamid-hydrochlorid
  • p-toluamid, N-isopropyl-a-(2-methylhydrazino)-, monohydrochlorid (8Cl)
  • PCB Hydrochlorid
  • Ro 4 6467/1
  • Ro 4-6467/1
  • NCI C01810
  • NCIC01810
Eksperimentel: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 antistof-lægemiddelkonjugat SGN-35
  • Anti-CD30 monoklonalt antistof-MMAE SGN-35
  • Anti-CD30 Monoklonalt Antistof-Monomethylauristatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Andre navne:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)

Undergo ISRT

Andre navne:
  • ISRT
Eksperimentel: Arm E (ABVD, AVD)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)
Eksperimentel: Arm F (ABVD, brentuximab vedotin, nivolumab)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 antistof-lægemiddelkonjugat SGN-35
  • Anti-CD30 monoklonalt antistof-MMAE SGN-35
  • Anti-CD30 Monoklonalt Antistof-Monomethylauristatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Andre navne:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)
Eksperimentel: Arm G (ABVD, eBEACOPP or eBPDac, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.

Given IV

Andre navne:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamid
  • 2H-1,3,2-Oxazaphosphorin, 2-[bis(2-chlorethyl)amino]tetrahydro-, 2-oxid, monohydrat
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamid
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrat
  • CYCLO-celle
  • Cykloblastin
  • Cycloblastin
  • Cyclofosfam
  • Cyclophosphamid monohydrat
  • Cyclophosphamid Monohydrat
  • Cyclophospamidum
  • Cyclofosfan
  • Cyclophosphanum
  • Cyclostin
  • Cytophosphan
  • Cytofosfan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimune
  • Syklofosfamid
  • WR- 138719
  • Asta B 518
  • B-518
  • WR-138719
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Given PO

Andre navne:
  • Deltasone
  • Orasone
  • 81-kortison
  • 1,2-dehydrocortison
  • Adasone
  • Cortancyl
  • Dacortin
  • DeCortin
  • Decortisyl
  • Decorton
  • Delta 1-kortison
  • Delta-Dome
  • Deltacortene
  • Deltacortison
  • Deltadehydrocortison
  • Deltison
  • Delta
  • Econosone
  • Lisacort
  • Meprosona-F
  • Metacortandracin
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracort
  • Perrigo Prednison
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Predniment
  • Prednison Intensol
  • Prednisonum
  • Predniton
  • Promifen
  • Rayos
  • Servisone
  • SK-Prednison

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Given IV

Andre navne:
  • Oncovin
  • Kyocristine
  • Leurocristinsulfat
  • Leurocristin, sulfat
  • Vincasar
  • Vincosid
  • Vincrex
  • Vincristin, sulfat

Ancillary studies

Given IV

Andre navne:
  • Demethyl Epipodophyllotoxin Ethylidin Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given IV

Andre navne:
  • Etopophos

Given PO

Andre navne:
  • (11beta)-11,17,21-Trihydroxypregna-1,4-dien-3,20-dion
  • 61-Hydrocortison
  • Adnisolon
  • Aprednislon
  • Kapsoid
  • Cortalone
  • Kortisolon
  • Dacortin H
  • Decaprednil
  • Decortin H
  • Delta(1)Hydrocortison
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-Phoricol
  • Delta1-dehydro-hydrocortison
  • Deltacortril
  • Deltahydrocortison
  • Deltasolone
  • Deltidrosol
  • Dhasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolon
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralon
  • Meti Derm
  • Meticortelone
  • Opredsone
  • Panafcortelone
  • Precortisyl
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolum
  • Prelone
  • Prenilon
  • Sterane

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)

Undergo ISRT

Andre navne:
  • ISRT

Given PO

Andre navne:
  • PCZ
  • Matulane
  • PCB
  • Natulanar
  • Benzamid, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-, monohydrochlorid (9Cl)
  • Ibenzmethyzinhydrochlorid
  • MIH hydrochlorid
  • Natulan
  • Naturalar
  • NCI-C01810
  • p-(N'-methylhydrazinomethyl)-N-isopropylbenzamid-hydrochlorid
  • p-toluamid, N-isopropyl-a-(2-methylhydrazino)-, monohydrochlorid (8Cl)
  • PCB Hydrochlorid
  • Ro 4 6467/1
  • Ro 4-6467/1
  • NCI C01810
  • NCIC01810
Eksperimentel: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm D.

Given IV

Andre navne:
  • Adriamycin
  • 5,12-naphthacendion, 10-[(3-amino-2,3,6-trideoxy-alfa-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy -8-(hydroxyacetyl)-1-methoxy-, hydrochlorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydrochlorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
  • FI106

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Ancillary studies

Given IV

Andre navne:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 antistof-lægemiddelkonjugat SGN-35
  • Anti-CD30 monoklonalt antistof-MMAE SGN-35
  • Anti-CD30 Monoklonalt Antistof-Monomethylauristatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Andre navne:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Given IV

Andre navne:
  • 4-(dimethyltriazeno)imidazol-5-carboxamid
  • 5-(dimethyltriazeno)imidazol-4-carboxamid
  • Asercit
  • Biocarbazin
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazin - DTIC
  • Dakatisk
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolcarboxamid
  • Dimethyl Triazeno Imidazol Carboxamide
  • dimethyl-triazeno-imidazolcarboxamid
  • Dimethyl-triazeno-imidazol-carboximid
  • DTIC
  • DTIC-Dome
  • Falsk
  • Imidazol Carboxamid
  • Imidazol Carboxamid Dimethyltriazeno
  • WR-139007

Given IV

Andre navne:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Andre navne:
  • Bleocin
  • Blenoxane
  • Blanoxan
  • BleMomycine
  • Bleo-celle
  • Bleo-S
  • Bleolem
  • Bleomycin Sulfas
  • Bleomycinsulfat
  • Bleomycini Sulfas
  • Blexane
  • Olie Bleo

Undergo CT and/or PET-CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo FDG-PET

Andre navne:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Undergo MRI and/or PET-MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)

Undergo ISRT

Andre navne:
  • ISRT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival (PFS) in rapid early responder (RER) patients
Tidsramme: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first

Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin-nivolumab) against those randomized to standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
PFS in slow-early responder (SER) patients
Tidsramme: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first

Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy against arms containing standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall survival (OS) in RER patients
Tidsramme: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years).

Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
OS in SER patients
Tidsramme: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients.

Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
OS for entire patient population
Tidsramme: Time from randomization to death due to any cause, assessed at 12 years after the last enrollment

Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization. Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population.

Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
PFS for favorable risk patients
Tidsramme: Up to 12 years

Will be estimated in patients with favorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
PFS for unfavorable risk patients
Tidsramme: Up to 12 years

Will be estimated in patients with unfavorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
PFS for entire population
Tidsramme: Up to 12 years

PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
Event-free survival (EFS)
Tidsramme: Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment

Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned versus (vs.) not assigned to receive radiaton therapy (RT), and compared using the log-rank test.

Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
Incidence of adverse events (AEs)
Tidsramme: Assessed up to 12 years from last enrollment

Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs. Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests. The maximum grade for each toxicity will be recorded for each patient. The rates and confidence intervals for these toxicities will be provided. Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients.

Assessed up to 12 years from last enrollment
Patient reported outcomes (PRO)-CTCAE
Tidsramme: Assessed up to 12 years from last enrollment

Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older. For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used. For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time. Additionally, the worst severity and/or interference over the entire course will be summarized. The changes among main time points will be calculated. The results will be provided for the whole population and compared between subpopulations by arms and by age groups. Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms.

Assessed up to 12 years from last enrollment
Patient-reported fatigue
Tidsramme: Baseline up to 1 year from end of study treatment

Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System initiatives. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Patient-reported cognitive deficits
Tidsramme: Baseline up to 1 year from end of study treatment

Will be measured by validated short forms from the Neuro-QoL initiative. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Patient-reported health-related quality of life
Tidsramme: Baseline up to 1 year from end of study treatment

Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Incidence of self-reported late morbidities
Tidsramme: Assessed up to 12 years from last enrollment

Will be collected by using validated measures from the St. Jude Life Cohort. The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method. The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests.

Assessed up to 12 years from last enrollment
Effect of metabolic tumor burden (MTV) on PFS
Tidsramme: At baseline prior to initiation of therapy

MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

At baseline prior to initiation of therapy
Effect of total lesion glycolysis (TLG) on PFS
Tidsramme: At baseline prior to initiation of therapy

TLG will be measured at baseline using FDG-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

At baseline prior to initiation of therapy
Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity
Tidsramme: After Cycle 2 of treatment (1 cycle = 28 days)

PET2 Response will be compared by race and ethnicity using Fisher exact tests.

After Cycle 2 of treatment (1 cycle = 28 days)
Contribution of SDOH to PFS by race and ethnicity
Tidsramme: Assessed up to 12 years after last enrollment

Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white [NHW], non-Hispanic black [NHB], Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.

Assessed up to 12 years after last enrollment
Contribution of SDOH to OS by race and ethnicity
Tidsramme: Assessed up to 12 years after last enrollment

K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.

Assessed up to 12 years after last enrollment

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PFS comparison between treatment arms for each age group
Tidsramme: Up to 12 years

Will be compared between a standard chemotherapy approach and an IO therapy approach within different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years) using log-rank tests. Cox regression models will be constructed to evaluate the treatment effects for different age groups while considering the impact of other potentially prognostic variables including baseline demographics and clinical risk factors. PFS and corresponding confidence intervals for each age group will be estimated with the Kaplan-Meier method, overall and by treatment arms. In additional models, age may be evaluated as a continuous variable with potentially non-linear effects on PFS.

Up to 12 years
Concordance and discordance of 5-point score (PS) visual PET assessments
Tidsramme: At baseline, post cycle 2, and at end of systemic therapy

The concordance and discordance of 5-PS visual PET assessment from rapid central review and local institutional review will be evaluated at each of the timepoints. Will collect and retrospectively review local vs. central review concordance rates. For discordant cases, will document the differences in treatments if only local review or only central review were performed

At baseline, post cycle 2, and at end of systemic therapy
Association between FDG PET parameters obtained by automated measurements and PFS
Tidsramme: At baseline, post cycle 2, and at the end of therapy

The association between FDG PET parameters obtained by automated measurements using convolutional neural networks and PFS will be evaluated in this aim. The PET parameters of interest are total MTV and TLG, tumor standardized uptake value change. PET parameters will be obtained based on artificial intelligence (AI) based measurements. The effect of these PET measurements will be evaluated by Cox regression models.

At baseline, post cycle 2, and at the end of therapy
Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement
Tidsramme: At baseline, post cycle 2, and at the end of therapy

Will compare AI derived automated quantitative FDG-PET measurement extraction and physician-based manual quantitative PET measurement with Spearman rank correlation coefficients for each extracted PET metric.

At baseline, post cycle 2, and at the end of therapy
Incidence of patient reported adverse events and provider adverse event reporting
Tidsramme: Assessed up to 12 years

Will be collected by PRO-CTCAE and Ped-PRO-CTCAE. The patient reported AEs will be compared to provider reported AEs reported descriptively.

Assessed up to 12 years
Association between self-reported race/ethnicity and dimensional SDOH
Tidsramme: Assessed up to 12 years

Will be evaluated by Chi-square tests or Fisher exact tests for sparse data. Will also calculate the area deprivation index (derived from patient-reported address and zip code to census block-group data for patients treated in the United States, and the Canadian Index of Multiple Deprivation for patients treated in Canada) and investigate its association with race/ethnicity and SDOH.

Assessed up to 12 years
Post-relapse/post-progression OS by race/ethnicity and select SDOH measures
Tidsramme: Assessed up to 12 years

The K-M curves will be presented together with p-values via log-rank tests across the different race/ethnicity groups for each treatment arm. Cox proportional hazard models to evaluate the relationship between race/ethnicity and post-relapse OS will be constructed.

Assessed up to 12 years
Completion rate of PRO and health-related quality of life contact forms
Tidsramme: At 1 year off treatment

Will be evaluated for the first 450 eligible participants.

At 1 year off treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Kara M Kelly, Roswell Park Cancer Institute

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. maj 2023

Primær færdiggørelse (Anslået)

28. april 2031

Studieafslutning (Anslået)

28. april 2031

Datoer for studieregistrering

Først indsendt

6. januar 2023

Først indsendt, der opfyldte QC-kriterier

6. januar 2023

Først opslået (Faktiske)

9. januar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NCI-2022-10845
  • U10CA180886 (U.S. NIH-bevilling/kontrakt)
  • NCI-2022-10845 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • AHOD2131 (Anden identifikator: CTEP)
  • AHOD2131 (Anden identifikator: Children's Oncology Group)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner